Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)
SCAN-B-rec: Infrastructure, Technology Platform and Clinical Research Development to Profile and Monitor Metastatic Breast Cancer
Lund University Hospital
2,000 participants
Jan 21, 2019
OBSERVATIONAL
Conditions
Summary
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure. The main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response/resistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.
Eligibility
Inclusion Criteria6
- Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease.
- Age \> 18 years.
- Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2.
- ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET).
- Patients must have a radiological evaluation done maximum 6 weeks prior to inclusion.
- Signed informed consent according to ICH/GCP, and national/local regulations.
Exclusion Criteria1
- Untreated psychiatric disorders that will impair the patient's ability to comply with study treatment or protocol.
Interventions
We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03758976